down arrow

ADC Therapeutics SA

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CH0499880968
USD
3.54
-0.41 (-10.38%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Kronos Bio, Inc.
Alpha Teknova, Inc.
DURECT Corp.
G1 Therapeutics, Inc.
ADC Therapeutics SA
Corvus Pharmaceuticals, Inc.
Werewolf Therapeutics, Inc.
Immix Biopharma, Inc.
Evelo Biosciences, Inc.
Tiziana Life Sciences Ltd.
Zynerba Pharmaceuticals, Inc.
Why is ADC Therapeutics SA ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -12.16
2
Flat results in Jun 25
  • EPS(Q) Lowest at USD -0.5
3
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 71.01%, its profits have risen by 26.4%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is ADC Therapeutics SA for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
ADC Therapeutics SA
71.01%
-0.02
116.18%
S&P 500
13.22%
0.65
20.20%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
112.90%
EBIT Growth (5y)
11.20%
EBIT to Interest (avg)
-12.16
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.07
Sales to Capital Employed (avg)
-0.33
Tax Ratio
0.62%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
77.95%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-1.62
EV to EBIT
-5.11
EV to EBITDA
-5.24
EV to Capital Employed
40.12
EV to Sales
8.46
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-785.24%
ROE (Latest)
Negative BV
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bullish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company
NET PROFIT(HY)

Higher at USD -82.16 MM

RAW MATERIAL COST(Y)

Fallen by -3.33% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -93.48 %

-1What is not working for the Company
EPS(Q)

Lowest at USD -0.5

Here's what is working for ADC Therapeutics SA
Net Profit
Higher at USD -82.16 MM
than preceding 12 month period ended Jun 2025
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Debt-Equity Ratio
Lowest at -93.48 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost
Fallen by -3.33% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for ADC Therapeutics SA
EPS
Lowest at USD -0.5
in the last five periods
MOJO Watch
Declining profitability; company has created lower earnings for shareholders

EPS (USD)

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."